Willi Steven M, Miller Kellee M, DiMeglio Linda A, Klingensmith Georgeanna J, Simmons Jill H, Tamborlane William V, Nadeau Kristen J, Kittelsrud Julie M, Huckfeldt Peter, Beck Roy W, Lipman Terri H
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania;
Jaeb Center for Health Research, Tampa, Florida;
Pediatrics. 2015 Mar;135(3):424-34. doi: 10.1542/peds.2014-1774.
Previous research has documented racial/ethnic disparities in diabetes treatments and outcomes. It remains controversial whether these disparities result from differences in socioeconomic status (SES) or other factors. We examined racial/ethnic disparities in therapeutic modalities and diabetes outcomes among the large number of pediatric participants in the T1D Exchange Clinic Registry.
The cohort included 10 704 participants aged <18 years with type 1 diabetes for ≥1 year (48% female; mean age: 11.9 ± 3.6 years; diabetes duration: 5.2 ± 3.5 years). Diabetes management and clinical outcomes were compared among 8841 non-Hispanic white (white) (83%), 697 non-Hispanic black (black) (7%), and 1166 Hispanic (11%) participants. The population included 214 high-income black and Hispanic families.
Insulin pump use was higher in white participants than in black or Hispanic participants (61% vs 26% and 39%, respectively) after adjusting for gender, age, diabetes duration, and SES (P < .001). Mean hemoglobin A1c was higher (adjusted P < .001) in black participants than in white or Hispanic participants (9.6%, 8.4%, and 8.7%). More black participants experienced diabetic ketoacidosis and severe hypoglycemic events in the previous year than white or Hispanic participants (both, P < .001). There were no significant differences in hemoglobin A1c, diabetic ketoacidosis, or severe hypoglycemia between white and Hispanic participants after adjustment for SES.
Even after SES adjustment, marked disparities in insulin treatment method and treatment outcomes existed between black versus Hispanic and white children within this large pediatric cohort. Barriers to insulin pump use and optimal glycemic control beyond SES should be explored in all ethnic groups.
先前的研究记录了糖尿病治疗及预后方面的种族/民族差异。这些差异是由社会经济地位(SES)的不同还是其他因素导致的,仍存在争议。我们在T1D交换诊所登记处的大量儿科参与者中,研究了治疗方式和糖尿病预后方面的种族/民族差异。
该队列包括10704名18岁以下患1型糖尿病至少一年的参与者(48%为女性;平均年龄:11.9±3.6岁;糖尿病病程:5.2±3.5年)。对8841名非西班牙裔白人(白人)(83%)、697名非西班牙裔黑人(黑人)(7%)和1166名西班牙裔(11%)参与者的糖尿病管理和临床预后进行了比较。该人群包括214个高收入黑人和西班牙裔家庭。
在调整了性别、年龄、糖尿病病程和SES后,白人参与者使用胰岛素泵的比例高于黑人和西班牙裔参与者(分别为61%、26%和39%)(P<.001)。黑人参与者的平均糖化血红蛋白水平高于白人和西班牙裔参与者(分别为9.6%、8.4%和8.7%)(校正后P<.001)。与白人和西班牙裔参与者相比,更多黑人参与者在过去一年中发生糖尿病酮症酸中毒和严重低血糖事件(均P<.001)。在调整SES后,白人和西班牙裔参与者在糖化血红蛋白、糖尿病酮症酸中毒或严重低血糖方面没有显著差异。
即使在调整SES后,在这个大型儿科队列中,黑人和西班牙裔儿童与白人儿童在胰岛素治疗方法和治疗结果方面仍存在明显差异。应在所有种族群体中探索除SES之外使用胰岛素泵和实现最佳血糖控制的障碍。